Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that presentations of clinical data for three product candidates employing its Targeted Antibody Payload (TAP) technology will be made at the 51^st American Society of Hematology (ASH) Annual Meeting and Exposition to be held in New Orleans, LA, on December 5-8, 2009.

Updated clinical findings will be reported on ImmunoGen’s IMGN901 TAP compound when used for the treatment of multiple myeloma. Additionally, the first clinical data will be reported for SAR3419 in the treatment of non-Hodgkin’s lymphoma and BT-062 in the treatment of multiple myeloma. These compounds are in development through the Company’s collaborations with sanofi-aventis and Biotest, respectively.

“Having clinical data presentations on multiple product candidates at ASH is reflective of the breadth of TAP compounds now advancing in the clinic,” commented Daniel Junius, President and CEO. “While TAP product candidates targeting solid tumors are attracting considerable attention, meaningful progress also is being made with therapies for the treatment of liquid tumors.”